< Back to previous page
Researcher
Peter Bossuyt
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Jun 2015 → Today
Publications
21 - 30 of 155
- Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial(2022)
Authors: Peter Bossuyt, Philippe Van Hootegem, Séverine Vermeire
Pages: 2074 - 2082 - Subtle Trap for the Inflammatory Bowel Disease Endoscopy Central Reader(2022)
Authors: Peter Bossuyt
Pages: 1849 - 1851 - Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials(2022)
Authors: Peter Bossuyt, Marc Ferrante
Pages: 2015 - 2030 - Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial(2022)
Authors: Marc Ferrante, Peter Bossuyt
Pages: 2031 - 2046 - A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence(2022)
Authors: Peter Bossuyt
Pages: 1511 - 1522 - Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study(2022)
Authors: Erwin Dreesen, Séverine Vermeire, Peter Bossuyt
Pages: 689 - 699 - LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS(2022)
Authors: Peter Bossuyt
Pages: S969 - S969 - PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE WITH AND WITHOUT PRIOR BIOLOGIC FAILURE DEMONSTRATED IMPROVED CLINICAL OUTCOMES WITH RISANKIZUMAB: RESULTS FROM PHASE 3 INDUCTION AND MAINTENANCE TRIALS(2022)
Authors: Peter Bossuyt
Pages: S974 - S974 - Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study.(2022)
Authors: Peter Bossuyt
Pages: 439 - 445 - Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial(2022)
Authors: Peter Bossuyt
Pages: 128 - 140